Related Experiment Video

Updated: Aug 4, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Platelet [3H]imipramine binding in migraine and tension headache in relation to depression

J Jarman1, P T Davies, M Fernandez

  • 1Department of Chemical Pathology, Queen Charlotte's and Chelsea Hospital, London, U.K.

Journal of Psychiatric Research
|January 1, 1991
PubMed

Insights

Migraine patients show reduced platelet imipramine binding, indicating a potential biomarker for migraine headaches. This reduction is linked to migraine itself, not associated depression or anxiety.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Platelet imipramine binding is a marker for serotonin transporter (SERT) activity.
  • Altered SERT function has been implicated in various neurological and psychiatric disorders.
  • Previous studies suggest potential differences in SERT binding in headache disorders.

Purpose of the Study:

  • To investigate platelet [3H]imipramine binding in patients with migraine and tension headaches compared to healthy controls.
  • To explore the relationship between platelet imipramine binding and psychological factors like depression and anxiety in migraine patients.

Main Methods:

  • Platelet-rich plasma was obtained from 40 migraine patients, 17 tension headache patients, and 28 normal controls.
  • Radioligand binding assays were performed using [3H]imipramine to measure binding capacity (Bmax).
  • Patients completed the Hospital Anxiety and Depression (HAD) Scale and underwent preliminary evaluation using the Schedule of Affective Disorders and Schizophrenia-Lifetime Version (SADS-L).

Main Results:

  • A statistically significant reduction in Bmax was observed in migraine patients compared to controls (p < 0.05).
  • No significant difference in Bmax was found between tension headache patients and controls.
  • No significant correlation was found between Bmax and HAD Scale scores for depression or anxiety in migraine patients.

Conclusions:

  • The study suggests a specific reduction in platelet imipramine binding in migraine, independent of comorbid depression or anxiety.
  • This finding may indicate an intrinsic neurobiological difference in serotonin transporter availability in migraine.
  • Platelet [3H]imipramine binding could serve as a potential biomarker for migraine pathophysiology.

More Related Videos

Investigating Migraine-Like Behavior Using Light Aversion in Mice05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Related Concept Videos

G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...